Clinical actionability by site of loss-of-function variants in genes other than BRCA1 and BRCA2
| Gene | Total no. of carriers | Relatives tested (n)(carriers) | Breast cancer surveillance | Ovarian cancer surveillance | Other cancer surveillance |
| CHEK2 | 43 | 21 (9) | Yes | No increased risk | Yes; colon |
| PALB2 | 23 | 29 (12) | Yes | Insufficient evidence | Insufficient evidence |
| ATM | 25 | 21 (7) | Yes | No increased risk | Insufficient evidence for PanCa/PrCa |
| TP53 | 20 | 12 (6) | Yes | No increased risk | Yes; multiple sites |
| RAD51C | 10 | 2 (2) | Insufficient evidence | Yes | Insufficient evidence |
| NBN | 6 | 6 (3) | Yes | Insufficient evidence | Insufficient evidence |
| PTEN | 4 | 4 (1) | Yes | No increased risk | Yes; endometrium, thyroid, colon |
| RAD51D | 4 | 2 (0) | Insufficient evidence | Yes | Insufficient evidence |
| PMS2 | 4 | 4 (2) | Insufficient evidence | Low/no increased risk | Yes; colon, endometrium, |
| MSH6 | 3 | 2 (0) | Insufficient evidence | Yes | Yes; endometrium, gastrointestinal tract |
| BRIP1 | 3 | 6 (1) | No increased risk | Yes | Insufficient evidence |
| MLH1 | 1 | 1 (0) | Insufficient evidence | Yes | Yes; endometrium, gastrointestinal tract |
| SDHB/C | 2 | 1 (0) | Insufficient evidence | No increased risk | Yes; paragangliomas |
| Total | 148 | 111 | 121 | 21 | 77 |
| Out of which 65 index | Out of which 18 index | Out of which 41 index |
Bold numbers indicate statistically significant findings.